Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production
- PMID: 15604543
- DOI: 10.1159/000081481
Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production
Abstract
Background: Zileuton, a 5-lipoxygenase inhibitor, reduces the number of inflammatory lesions in moderate acne and inhibits the synthesis of sebaceous lipids.
Objective: To detect whether zileuton directly reduces sebum synthesis.
Methods: A 40-year-old female with mild disseminated sebaceous gland hyperplasia and seborrhea was treated with zileuton 4 x 600 mg/day over 2 weeks, was followed-up for 6 weeks after discontinuation of zileuton and was re-treated with low-dose isotretinoin 10 mg/2nd day over 5 weeks. Casual skin surface lipids and sebum synthesis were determined.
Results: Under treatment with zileuton increased casual skin surface lipids were normalized and synthesis of facial sebum was decreased. Six weeks after discontinuation of treatment casual skin surface lipids were increased again and synthesis of sebum returned to baseline. Subsequent low-dose isotretinoin treatment led to similar changes of casual skin surface lipids and sebum synthesis with zileuton already after 2 weeks.
Conclusion: Zileuton directly inhibits sebum synthesis in a transient manner with a potency similar to low-dose isotretinoin at least in our patient.
Similar articles
-
Zileuton, a new efficient and safe systemic anti-acne drug.Dermatoendocrinol. 2009 May;1(3):188-92. doi: 10.4161/derm.1.3.8368. Dermatoendocrinol. 2009. PMID: 20436887 Free PMC article.
-
Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial.Int J Dermatol. 2017 Jan;56(1):80-85. doi: 10.1111/ijd.13408. Epub 2016 Oct 25. Int J Dermatol. 2017. PMID: 27778328 Clinical Trial.
-
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.JAMA. 1996 Mar 27;275(12):931-6. JAMA. 1996. PMID: 8598621 Clinical Trial.
-
Acne and sebaceous gland function.Clin Dermatol. 2004 Sep-Oct;22(5):360-6. doi: 10.1016/j.clindermatol.2004.03.004. Clin Dermatol. 2004. PMID: 15556719 Review.
-
Botulinum Neurotoxin Type A in the Treatment of Facial Seborrhea and Acne: Evidence and a Proposed Mechanism.Toxins (Basel). 2021 Nov 19;13(11):817. doi: 10.3390/toxins13110817. Toxins (Basel). 2021. PMID: 34822601 Free PMC article. Review.
Cited by
-
[Pathophysiology of acne].Hautarzt. 2005 Nov;56(11):1013-7. doi: 10.1007/s00105-005-1043-1. Hautarzt. 2005. PMID: 16215770 Review. German.
-
Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise.Dermatoendocrinol. 2011 Jul;3(3):130-5. doi: 10.4161/derm.3.3.15025. Epub 2011 Jul 1. Dermatoendocrinol. 2011. PMID: 22110772 Free PMC article.
-
Zileuton, a new efficient and safe systemic anti-acne drug.Dermatoendocrinol. 2009 May;1(3):188-92. doi: 10.4161/derm.1.3.8368. Dermatoendocrinol. 2009. PMID: 20436887 Free PMC article.
-
Linoleic Acid Induced Changes in SZ95 Sebocytes-Comparison with Palmitic Acid and Arachidonic Acid.Nutrients. 2023 Jul 26;15(15):3315. doi: 10.3390/nu15153315. Nutrients. 2023. PMID: 37571253 Free PMC article.
-
Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy.PLoS One. 2013 Jun 24;8(6):e65928. doi: 10.1371/journal.pone.0065928. Print 2013. PLoS One. 2013. PMID: 23826084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases